Cartography raises $67 million in Series B financing led by Pfizer Ventures to advance its oncology pipeline, including the lead program CBI-1214 into Phase 1 trials.
Cartography Biosciences, Inc. has secured $67 million in Series B financing to support its oncology programs. The funding will help advance its lead program, CBI-1214, into the clinic. Pfizer Ventures led the round, joined by other investors like LG Corp and Amgen Ventures
Who to call at Cartography Biosciences, and when
A new round usually means Cartography Biosciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Cartography Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Cartography Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cartography Biosciences. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Cartography Biosciences
Location
San Francisco, California, United States
About
Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography’s ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across the healthy body and large-scale profiling of individual cells from patient tumors. By leveraging petabytes of proprietary data, along with insights from machine learning and AI, Cartography is identifying and developing therapeutics against highly specific targets and target pairs to build a pipeline of molecules with the greatest patient impact. Cartography’s lead program in preclinical development, CBI-1214, is a T-cell engager being advanced for CRC.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cartography Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnology